22 completed, 7 terminated, 4 recruiting, 4 withdrawn. 21 Phase 2, 17 Phase 1, 4 Phase 3, 2 Not applicable.
Follow tivozanib: new trials by email Literature Review of tivozanib trials Research Report on tivozanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer Pembrolizumab, Tivozanib, Biospecimen Collection - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1040 | 2025-03-14 | 2026-09-02 |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2024-01-05 | 2026-10-07 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers Tivozanib - Cholangiocarcinoma, Bile Duct Neoplasm | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2022-03-04 | 2026-10-16 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 3 | Completed | AVEO Pharmaceuticals, Inc. | 343 | 2021-09-09 | 2026-05-08 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Tivozanib, Durvalumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 27 | 2019-09-30 | 2023-07-12 |
| Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC Tivozanib, Nivolumab - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Completed | AVEO Pharmaceuticals, Inc. | 28 | 2017-03-22 | 2021-12-06 |
| Tivozanib As Maintenance Therapy In GYN Tivozanib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 4 | 2013-11-01 | 2017-06-05 |
| A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation Tivozanib, Erlotinib, Standard of Care treatment - Non-small Cell Lung Cancer, Stage IV Disease | Phase 1 / Phase 2 | Withdrawn | University of Utah | 2013-11-01 | 2013-07-25 | |
| Tivozanib + Enzalutamide in Adv Prostate Cancer Tivozanib, Enzalutamide - Prostate Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 5 | 2013-09-03 | 2026-05-20 |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery Tivozanib (1mg), Tivozanib (1.5mg) - Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 33 | 2013-07-11 | 2020-10-28 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Tivozanib - Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Completed | Northwestern University | 31 | 2013-06-06 | 2021-10-12 |
| Tivozanib for Recurrent Glioblastoma Tivozanib - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 10 | 2013-06-01 | 2019-01-08 |
| Tivozanib + Gemcitabine in Metastatic RCC Tivozanib, Gemcitabine - Renal Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2013-06-01 | 2013-06-19 | |
| Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer tivozanib, therapeutic conventional surgery - Stage II Renal Cell Cancer, Stage III Renal Cell Cancer | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2013-03-14 | 2022-08-15 | |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas tivozanib, laboratory biomarker analysis - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Completed | Northwestern University | 58 | 2013-03-06 | 2019-09-09 |
| Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer Tivozanib - Hepatocellular Cancer | Phase 2 | Terminated | Emory University | 7 | 2013-03-01 | 2016-04-22 |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer Tivozanib Hydrochloride, paclitaxel, Placebo - Triple Negative Breast Cancer | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 30 | 2012-11-01 | 2020-10-27 |
| A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC Tivozanib, Sunitinib - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 58 | 2012-07-01 | 2020-10-27 |
Showing 20 of 37. Sign in to see all of them.
Carcinoma, Renal Cell (11) · Colorectal Neoplasms (4) · Breast Neoplasms (3) · Bile Duct Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Gastrointestinal Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1)
AVEO Pharmaceuticals, Inc. (20) · Dana-Farber Cancer Institute (3) · Massachusetts General Hospital (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Emory University (1) · Kyowa Kirin Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Florida (1) · University of Utah (1)
United States (31) · Canada (7) · Italy (6) · France (5) · Ukraine (5) · United Kingdom (5) · Czechia (4) · Germany (4) · India (4) · Russia (4) · Spain (4) · Australia (3) · Belgium (3) · Chile (3) · Hungary (3)
Joshua Zhang, M.D. (2) · Robert J. Motzer, MD (2) · Anna Berkenblit, MD (1) · Bassel El-Rayes, MD (1) · Brian Wolpin, MD (1) · Chao Huang, MD (1) · Charles B Nguyen (1) · Daniela Matei, MD (1) · Dennis Vargo, MD (1) · Dmitriy G Nosov, M.D. (1) · Elizabeth Gerstner, MD (1) · Eric Jonasch, M D (1) · Erica Mayer, M.D. (1) · Ferry Eskens, MD, PhD (1)
PMID 23580238, PMID 23726267, PMID 25591799, PMID 27771610, PMID 32037403, PMID 33010459, PMID 33101775, PMID 33445053, PMID 34071188, PMID 35304832, PMID 36399037, PMID 36912078, PMID 37146227, PMID 37185961, PMID 37315114, PMID 39284329
2009 (1), P30CA016056 (1), P30CA033572 (1)